
Immutep Ltd (IMMP) Stock Forecast & Price Target
Immutep Ltd (IMMP) Analyst Ratings
Bulls say
Immutep Ltd is advancing its lead product candidate, eftilagimod alfa (efti), through a registrational Phase three clinical trial for first-line non-small cell lung cancer, where efti has demonstrated significant efficacy, particularly in patients with less responsive tumor types, increasing overall response rates substantially. The company's robust patent portfolio and the product's compatibility with existing PD-(L)1 therapies present opportunities for significant market expansion and the establishment of new treatment franchises. Such advancements underscore a positive outlook for Immutep's stock, reflecting the potential for enhanced patient outcomes and commercial success in the oncology sector.
Bears say
Immutep Ltd faces a negative outlook primarily due to concerns regarding the underwhelming clinical results of its lead product candidate, eftilagimod alfa (efti), which has led to a significant reduction in the projected probability of success in non-small cell lung cancer (NSCLC) to just 30%. Additionally, the company's focus on LAG-3 antagonists, which have historically shown mixed results in lung cancer, contributes to skepticism about their potential to be transformative in this treatment landscape. Furthermore, lower efficacy outcomes related to the increased proportion of patients with low tumor proportion score (TPS) seen in the ongoing INSIGHT-003 trial further diminish confidence in the commercial viability of Immutep's therapies.
This aggregate rating is based on analysts' research of Immutep Ltd and is not a guaranteed prediction by Public.com or investment advice.
Immutep Ltd (IMMP) Analyst Forecast & Price Prediction
Start investing in Immutep Ltd (IMMP)
Order type
Buy in
Order amount
Est. shares
0 shares